Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / HEALTHCAREFINANCE     showing 1–2 of 2   RSS


for: Wednesday, March 18, 2026



Sutter, Allina Health Combine to Form $26B Health System

Katie Adams / medcitynews - Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising …

AI Summary: Sutter Health and Allina Health have agreed to combine in a transaction that would create a $26 billion nonprofit system spanning California and Minnesota, forming a 39‑hospital network. The deal aims to consolidate operations and expand market reach, subject to definitive agreements and regulatory approvals, promising scale-driven efficiencies — and inevitably, some rebranded parking lots.


Close watch: finances, approvals and expected closing timeline


On the ground: Sutter and Allina agree to $26B merger

2 months / fiercehealthcare


Other developments: regional hospital expansions and financing moves


Trend watch: consolidation reshaping hospital markets nationwide


All Other Stories



‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug

Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…

AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #healthcarefinance #clinicaltrials

2 months / medicalxpress


Back to Top / Wednesday, March 18, 2026, 4:23 pm / permalink 20957 / 3 stories in 2 months /

Back to Top


HEALTHCAREFINANCE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Zoonotic Disease, Hospital Operations, Supplements, Novo Nordisk and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.